Galderma, with Oracea looking for Inflammatory Pathway Markers

Seemingly wanting to help answer the question How do tetracyclines help Rosacea? Galderma has announced a large trial to measure the changes in inflammatory pathway markers when you take Oracea.

Whilst the trial only directly mentions LL-37 and MMP I would expect other well known markers to be measured as well.

If the researchers include markers that can be proven to be indicative of rosacea disease, and these markers show a statistical difference compared to placebo participants, then this study could then lead to something important regarding the progression of rosacea.

Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea  vs Placebo

The objective of this study is to determine the clinical effects of doxycycline 40 mg (30 mg immediate release and 10 mg delayed release beads) capsules (Oracea) as compared to placebo in the skin of adults with papulopustular rosacea and to identify a correlation, if any, with rosacea-related inflammatory markers.

Mean change from baseline to week 12 in biochemical markers of rosacea and expression in skin samples. A biological marker is a substance used as an indicator of a biological state such as rosacea. Biochemical markers are serine protease activity and expression, metalloprotease activity and expression, and production of leucine leucine-37 [LL-37] peptide.

Related Articles

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed Connect on Pinterest Connect on Google Plus

Leave your comment here

Top

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.